KR444.7 M

IMMU.ST Mkt cap, 17-Jun-2022
Immunicum Gross profit (FY, 2021)9 K
Immunicum Net income (FY, 2021)-133.4 M
Immunicum EBITDA (FY, 2021)-129.1 M
Immunicum EBIT (FY, 2021)-130.1 M
Immunicum Cash, 31-Dec-2021155.3 M
Immunicum EV289.7 M
Get notified regarding key financial metrics and revenue changes at ImmunicumLearn more
Banner background

Immunicum Revenue Breakdown

Embed Graph

Immunicum revenue breakdown by business segment: 100.0% from PHARMACEUTICAL BIOLOG/VACCINES

Immunicum Income Statement

Annual

SEKFY, 2018FY, 2019FY, 2020FY, 2021

Revenue

16.7m

Gross profit

184.0k16.7m9.0k

R&D expense

(70.7m)(49.0m)(47.9m)(85.8m)

Operating expense total

(98.0m)(60.7m)(85.1m)(129.1m)

Depreciation and amortization

(60.0k)(832.0k)(887.0k)(993.0k)

EBITDA

(97.8m)(44.0m)(85.1m)(129.1m)

EBIT

(97.8m)(44.9m)(86.0m)(130.1m)

Interest expense

(14.0k)(2.9m)(3.2m)(3.3m)

Pre tax profit

(97.9m)(47.8m)(89.2m)(133.4m)

Net Income

(97.9m)(47.8m)(89.2m)(133.4m)

Immunicum Balance Sheet

Annual

SEKFY, 2018FY, 2019FY, 2020FY, 2021

Cash

443.8m14.0m167.6m155.3m

Prepaid Expenses

2.3m1.1m8.0m13.1m

Inventories

1.5m

Current Assets

450.4m33.2m192.6m185.2m

PP&E

9.0k2.2m1.7m2.1m

Goodwill

108.4m108.4m

Total Assets

450.4m37.9m728.7m721.0m

Accounts Payable

31.3m1.9m10.4m11.6m

Short-term debt

871.0k880.0k309.0k

Current Liabilities

43.5m11.3m48.3m27.6m

Long-term debt

850.0k1.2m303.0k

Non-Current Liabilities

850.0k32.3m19.3m36.7m

Total Debt

850.0k2.1m1.2m309.0k

Total Liabilities

44.3m43.6m67.6m64.2m

Common Stock

4.6m586.0k8.3m10.0m

Additional Paid-in Capital

731.1m258.0m1.0b1.1b

Retained Earnings

(329.6m)(264.5m)(353.8m)(487.2m)

Total Equity

406.0m(5.7m)661.1m656.7m

Immunicum Cash Flow

Annual

SEKFY, 2018FY, 2019FY, 2020FY, 2021

Net Income

(97.8m)(44.9m)(86.0m)(130.1m)

Accounts Receivable

5.4m(14.1m)22.2m(4.4m)

Accounts Payable

19.6m(3.3m)761.0k10.7m

Cash From Operating Activities

(104.7m)(57.6m)(56.6m)(138.0m)

Cash From Investing Activities

(809.0k)157.3m(1.4m)

Long-term Borrowings

(760.0k)(725.0k)(1.9m)

Cash From Financing Activities

419.6m67.1m50.9m127.0m

Net Change in Cash

314.9m9.6m153.6m(12.3m)

Immunicum Ratios

SEKFY, 2018